{"id":"W2896812857","doi":"10.1136/annrheumdis-2018-eular.3115","title":"SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada); Toronto Western Hospital; University of Toronto","funders":"Sun Pharma; Genentech; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tofacitinib; Medicine; Janus kinase inhibitor; Psoriatic arthritis; Tolerability; Adverse effect; Internal medicine; Discontinuation; Interim analysis; Clinical endpoint; Gastroenterology; Surgery; Arthritis; Randomized controlled trial; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002770115,0.00131112,0.00301809,0.0005042175,0.0005574588,0.001707757,0.0006899764,0.001316,0.003768868],"category_scores_gemma":[0.001760647,0.0004808103,0.004413841,0.0006920274,0.0007173585,0.001381919,0.0003931537,0.003214322,0.001241825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006442487,"about_ca_system_score_gemma":0.00105542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008711727,"about_ca_topic_score_gemma":0.001731966,"domain_scores_codex":[0.9990409,0.0003783779,0.00009007489,0.0001279043,0.0001616374,0.0002011015],"domain_scores_gemma":[0.9987337,0.000345083,0.0003381552,0.0001936537,0.0001258783,0.0002635444],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9255394,0.004549987,0.008348547,0.0005629616,0.004046176,0.00015679,0.000105169,0.001706312,0.008242266,0.0001082957,0.001715213,0.04491883],"study_design_scores_gemma":[0.60282,0.25822,0.114324,0.0001619218,0.01109671,0.000578432,0.0001808472,0.002577916,0.005070389,0.0005877152,0.004238376,0.0001436663],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987097,0.005811131,0.0004204866,0.0003027386,0.0001453047,0.0002871817,0.003536343,0.0001206559,0.002279153],"genre_scores_gemma":[0.9909484,0.001439048,0.0003807283,0.0004524847,0.000152601,0.0003056198,0.004869816,0.00002876281,0.00142257],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003768868,"threshold_uncertainty_score":0.01464993,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06990249752259424,"score_gpt":0.3735381835484743,"score_spread":0.30363568602588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}